Sign inSubmit
ArticleMetrics
Research Article · Open access · Published 29 December 2021

Release of Endogenous Chondroitin Sulfate and Heparin as Consequence of Dysregulated Proteolysis in COVID-19

Marco Ruggiero1

American Journal of Immunology, Volume 17, Issue 1, pp. 40–46 · doi.org/10.3844/ajisp.2021.40.46

7,688 accesses4,012 downloads0 citations (Crossref)Metrics
Cite Check for updates

Abstract

Infection by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, is associated with immune-mediated responses that lead to dysregulated activation of proteolytic enzymes; these contribute to damage to the endothelium, thrombosis, hypercoagulability and other hematologic complications that include thrombotic thrombocytopenia, a complication of severe COVID-19 as well as a potentially fatal adverse effect of COVID-19 vaccination. The aim of this study is to demonstrate the hypothesis that thrombotic thrombocytopenia is associated with and possibly due, to proteolysis of human plasma proteins leading to sequential release of endogenous Glycosaminoglycans (GAGs), first Chondroitin Sulfate (CS), followed by Heparin (HP). This hypothesis is based on experiments on healthy human plasma performed at the Department of Experimental Pathology and Oncology, University of Florence, Italy. The results of those experiments are here reported and reinterpreted at the light of the complications of COVID-19. Based on those results, it is hypothesized that the extension and degree of what is called "proteolytic storm" in COVID-19 determines whether only one endogenous type of GAGs (CS), or both (CS and HP), are released. Sulfated GAGs such as CS and HP exert a protective role against SARS-CoV-2 infection. However, sustained and excessive release of endogenous HP may be responsible for thrombotic thrombocytopenia just as it happens in HP-Induced Thrombocytopenia (HIT) a well-known side effect of HP administration that results in thromboembolisms in atypical sites, thrombocytopenia and synthesis of autoantibodies directed against Platelet Factor 4 (PF4) that contribute to platelet aggregation. It is concluded that release of endogenous HP as consequence of dysregulated proteolysis occurring during COVID-19 or COVID-19 vaccination may play a fundamental role in the pathophysiology of the disease as well as in adverse reactions to vaccination.

Licence and reuse

Open access. This article is licensed under a Creative Commons Attribution 4.0 International Licence (CC BY 4.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.

How to reuse this article

Responses (0)

Have a comment on this research? Sign in to respond. Responses are moderated and published with your name and affiliation; the authors are invited to reply. How we use your dataWrite a response

About this article

Cite this article

Ruggiero, M. (2021). Release of Endogenous Chondroitin Sulfate and Heparin as Consequence of Dysregulated Proteolysis in COVID-19. American Journal of Immunology, 17(1), 40–46. https://doi.org/10.3844/ajisp.2021.40.46

Licence
CC BY 4.0
Issue
Volume 17, Issue 1
Policies
Editorial independenceUse of generative AIData availabilityAppeals and complaints
Version
Version of record
Release of Endogenous Chondroitin Sulfate and Heparin as Consequence of Dysregulated Proteolysis in COVID-19American Journal of Immunology · Volume 17, Issue 1 · pp. 40–46 · CC BY 4.0Download